Synthesis and docking studies of some novel quinoline derivatives bearing a sulfonamide moiety as possible anticancer agents

Mostafa M. Ghorab; Fatma A. Ragab; Mostafa M. Hamed

doi:10.1055/s-0031-1296263

Arzneimittelforschung, Inhaltsverzeichnis

Arzneimittelforschung 2010; 60(3): 141-148
DOI: 10.1055/s-0031-1296263

Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics

Editio Cantor Verlag Aulendorf (Germany)

Synthesis and docking studies of some novel quinoline derivatives bearing a sulfonamide moiety as possible anticancer agents

Mostafa M. Ghorab

¹Department of Drug Radiation Research, National Centre for Radiation Research and Technology, Atomic Energy Authority, Nasr City, Cairo, (Egypt)

,

Fatma A. Ragab

²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, (Egypt)

,

Mostafa M. Hamed

³Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, New Cairo City, (Egypt)

› Institutsangaben

Abstract

Sulfonamides posses many types of biological activities and have recently been reported to show substantial antitumor activity in vitro and/or in vivo. There is a variety of mechanisms for the anticancer activity of the sulfonamide compounds and the most prominent of these is the inhibition of carbonic anhydrase isozymes. The present work reports the synthesis of some novel quinoline and pyrimido [4,5-b] quinoline derivatives bearing a sulfonamide moiety. The structures of these compounds were confirmed by elemental analysis, IR, ¹H-NMR and mass spectral data. All the newly synthesized compounds were evaluated for their in vitro anticancer activity against breast cancer cell line (MCF7). Most of the screened compounds showed interesting cytotoxic activities compared with the used reference drugs. In addition, docking of the synthesized compounds into carbonic anhydrase isozyme II (CA II) active site was performed in order to predict the affinity and the orientation of these compounds at the isozyme active site.

Key words

Anticancer agents Carbonic anhydrase Quinolines Sulfonamide

Volltext

Referenzen

References
1 Drews J. Drug discovery: a historical perspective. Science. 2000; 287 (5460) 1960-4
2 Boyd AE. 3rd. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes. 1988; 37 (7) 847-50
3 Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents. 2000; 10: 575-600
4 Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol. 1976; 16: 309-27
5 Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem Immunol Endocr Metab Agents. 2001; 1: 61-97
6 Thornber CW. Isosterism and Molecular Modification in Drug Design. Chem Soc Rev. 1979; 8: 563-80
7 Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004; 14 (1) 217-23
8 Ghorab MM, Noaman E, Ismail MM, Heiba HI, Ammar YA, Sayed MY. Novel antitumor and radioprotective sulfonamides containing pyrrolo[2,3-d]pyrimidines. Arzneimittelforschung. 2006; 56 (6) 405-13
9 Ismail MM, Ghorab MM, Noaman E, Ammar YA, Heiba HI, Sayed MY. Novel synthesis of pyrrolo[2,3-d]pyrimidines bearing sulfonamide moieties as potential antitumor and radioprotective agents. Arzneimittelforschung. 2006; 56 (4) 301-8
10 Rostom SA. Synthesis and in vitro antitumor evaluation of some indeno[l,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg Med Chem. 2006; 14 (19) 6475-85
11 Supuran CT, Casini A, Mastrolorenzo A, Scozzafava A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med Chem. 2004; 4 (6) 625-32
12 Kivela AJ, Kivela J, Saarnio J, Parkkila S. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol. 2005; 11 (2) 155-63
13 Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discovery. 2008; 7 (2) 168-81
14 Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem. 2007; 15 (13) 4336-50
15 Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Anticancer and antiviral sulfonamides. Curr Med Chem. 2003; 10 (ll) 925-53
16 Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets. 2002; 2 (l) 55-75
17 Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 2004; 19 (3) 199-229
18 Saczewski F, Slawinski J, Kornicka A, Brzozowski Z, Pomarnacka E, Innocenti A et al. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg Med Chem Lett. 2006; 16 (18) 4846-51
19 Saczewski F, Innocenti A, Slawinski J, Kornicka A, Brzozowski Z, Pomarnacka E et al. Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. Bioorg Med Chem. 2008; 16 (7) 3933-40
20 Chegwidden WRS, Spencer IM. Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture. Inflammopharmacology. 1995; 3: 231-9
21 Gopal M, Shenoy S, Doddamani LS. Antitumor activity of 4-amino and 8-methyl-4-(3diethylamino propylamino)pyrimido[4’,5’:4,5]thieno(2,3-b)quinolines. J Photochem Photobiol B. 2003; 72 (1–3) 69-78
22 Kim YH, Shin KJ, Lee TG, Kim E, Lee MS, Ryu SH et al. G2 arrest and apoptosis by 2-amino-N-quinoline-8-yl-benzenesulfonamide (QBS), a novel cytotoxic compound. Biochem Pharmacol. 2005; 69 (9) 1333-41
23 Zhao YL, Chen YL, Chang FS, Tzeng CC. Synthesis and cytotoxic evaluation of certain 4-anilino-2-phenylquinoline derivatives. Eur J Med Chem. 2005; 40 (8) 792-7
24 Liou JP, Wu ZY, Kuo CC, Chang CY, Lu PY, Chen CM et al. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. J Med Chem. 2008; 51 (14) 4351-5
25 Ghorab MM, Ragab FA, Noaman E, Heiba HI, El-Hossary EM. Synthesis of some novel quinolines and pyrimido[4,5b]quinolines bearing A sulfonamide moiety as potential anticancer and radioprotective agents. Arzneimittelforschung. 2007; 57 (12) 795-803
26 Ghorab MM, Ragab FA, Noaman E, Heiba HI, El-Hossary EM. Utility of 4-(5,5-dimethyl-3-oxo-cyclohex-l-enylamino)benzenesulfonamide in the synthesis of novel quinolines as possible anticancer and radioprotective agents. Arzneimittelforschung. 2008; 58 (1) 35-41
27 Al-Afaleq EI, Abubshait SA. Heterocyclic o-aminonitriles: preparation of pyrazolo[3,4-d]-pyrimidines with modification of the substituents at the 1-position. Molecules. 2001; 6: 621-38
28 Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82 (13) 1107-12
29 Tacconi G, Gatti G, Desimoni G, Messori V. A new route to 4H-pyrano[2,3-c]pyrazoles. J Prakt Chem. 1980; 322 (5) 831-4